Introduction: Childhood-onset, or juvenile-onset SLE (JSLE) is rare, complex and can lead to significant associated morbidity and mortality. Evidence-based guidelines are sparse and management is mostly based on physician experience. Consequently, treatment regimens differ widely between centres and throughout Europe and beyond. Objectives: To provide an update on UK and European initiatives and progress in optimising the care and understanding of JSLE. Specific focus will be on key challenges impacting on young people with lupus, accumulation of damage as they prepare to transition to adults, and European recommendations for the diagnosis and management of childhood-onset SLE. Methods: Since 2006, the UK JSLE Study Group has fostered a UKwide translational programme of research directed towards future clinical trials in JSLE. This UK-wide multi-disciplinary, multi-centre collaborative group comprises all UK tertiary paediatric rheumatology and nephrology centres. At the heart of this has been developing from inception the UK JSLE Cohort Study & Repository. Recruiting from 21 UK-sites over 500 patients, it forms one of the largest national cohorts of JSLE in the world. It enables exploration of the clinical and immunopathological characteristics of this archetypal systemic autoimmune disease, and fosters a robust translational programme of research directed towards clinical trials in JSLE. It has set a consensus UK-wide standard of care for the assessment, diagnosis, monitoring and follow-up of patients with JSLE. In 2013, a European initiative called SHARE (Single Hub and Access point for paediatric Rheumatology in Europe) was launched to optimise and disseminate guidelines for diagnosis and management for children and young adults with paediatric rheumatic diseases within Europe, including childhood-onset SLE. Results: An overview of the work of the UK JSLE Study Group will be presented, focussing on disease accumulation, medication burden (including corticosteroid usage), and organ damage (both disease-and medication-related) already in adolescence, that becomes a significant burden as they transition to adult care. A summary of the final consensus SHARE recommendations will be presented for SLE. These provide evidence based, internationally agreed standards of minimal care for children and young people with lupus. They provide a critical platform for improving the care and minimising the future impact and damage of this complex disease. Conclusions: Significant progress has been made, nationally and internationally, in providing an evidence-base for improving our understanding, diagnosis and management of SLE in young people. This provides a key opportunity to improve the outcomes of children as they transition to adult care and throughout their adult lives. Disclosures: M.B. consultancies; Aurina -to Institution, not personal. Grants/research support; LUPUS UK, Arthritis Research UK, Local charities.
I048 ADULT SLE: SURVIVORS FROM CHILDHOOD ONSET
Anisur Rahman 1 1 Rheumatology, University College London, London, UNITED KINGDOM Patients who developed lupus in childhood or adolescence arrive in the adult clinic having been exposed to the disease for many years. Since lupus nephritis is more common in childhood/adolescent onset lupus these patients may have a higher incidence of renal damage and chronic renal impairment. It is important to be watchful for onset of end-stage renal failure. Cardiovascular disease, incorporating myocardial infarction and stroke, is considerably more common in patients with SLE than in age/sex matched controls without SLE. The reasons for this are not fully understood but exposure to drugs (e.g. high dose corticosteroids) and to prolonged systemic inflammation may contribute to the increased risk of CVD. Both these factors apply to patients who developed their lupus in childhood or adolescence, so it is important to look out for cardiovascular events especially in those with positive blood tests for antiphospholipid antibodies. Another issue that may arise in these patients is long-term side-effects from having taken medications in childhood and adolescence, for example early onset of osteoporosis and issues related to fertility. Lastly, the consultations in this group of patients may be slightly different from other lupus consultations. They may bring a parent with them and may have definite views about therapy (such as taking corticosteroids) based on their long previous experience of SLE. Disclosures: A.R. is an inventor on a patent submitted for a new agent in treatment of APS, working with PolyTherics Limited, A.R. gave a talk at a meeting in Japan sponsored by Chugai Pharmaceuticals in July 2017. A.R. is a member of an adjudication committee for a clinical trial run by Neovacs.
I049 THE IMPORTANCE OF IDENTIFYING AND MANAGING CO-MORBID ANXIETY AND DEPRESSION IN PEOPLE WITH RHEUMATOLOGICAL CONDITIONS
Carolyn Chew-Graham 1 1 Primary Care & Health Sciences, Keele University, Keele, UNITED KINGDOM Anxiety and depression are common mental disorders and major contributors to the overall global burden of disease. Depression is a risk factor for suicide. Where anxiety and depression are co-morbid with a long term physical condition, the morbidity and mortality from the long-term condition(s) are worsened. Anxiety and depression are commonly co-morbid with inflammatory arthritis, often un-detected and under-treated, and can lead to reduced treatment response, and increased morbidity and mortality. There is a good evidence-base for the effectiveness of individual treatments for people with anxiety and depression, but there are barriers to access for treatment, including stigma associated with mental disorders, normalisation of symptoms by both patients and health care professionals, inaccurate assessment, reliance on prescribing antidepressants, and lack of commissioned services offering evidence-based talking treatments. These barriers are exacerbated when anxiety and depression are co-morbid with long-term conditions. Most people with depression will be managed in primary care, without recourse to specialist mental health services. Collaborative care, incorporating a multiprofessional approach to patient care; a structured management plan; scheduled patient follow-ups; and enhanced communication has the potential to improve the management of people with co-morbid depression and anxiety. This presentation will use cases to illustrate approaches to the detection and management of people with inflammatory arthritis and co-morbid anxiety and depression, and make suggestions to improve both patient outcomes and relationships across the primary/specialist care interface. Disclosures: C.C-G. royalties; received for ABC of Anxiety and Depression, received for ABC of Anxiety and Depression. Honoraria; Honoraria received to deliver training at RCGP conferences on Mental Health, Honoraria received to deliver training at RCGP conferences on Mental Health. Grants/research support; various NIHR-funded applications to evaluate mental health interventions in primary care. CLAHRC and Haywood Foundation funding to evaluate nurse review of people with inflammatory arthritis. Various NIHR-funded applications to evaluate mental health interventions in primary care. CLAHRC and Haywood Foundation funding to evaluate nurse review of people with inflammatory arthritis. Various NIHR-funded applications to evaluate mental health interventions in primary care. CLAHRC and Haywood Foundation funding to evaluate nurse review of people with inflammatory arthritis. 
I050 PSYCHOLOGICAL APPROACHES TO PAIN AND ASSOCIATED COMORBIDITIES IN PATIENTS WITH CHRONIC PHYSICAL HEALTH CONDITIONS

